Latest Filings

Issuer Activity

Overview :: ACADIA Pharmaceuticals Inc. (OQ:ACAD) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for ACAD
USD 21.210 +0.470 (+2.266%)
NSQ Delayed 15 minutes
Jul 30 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
21.490 32.000 N/A 808,836 2,099.29
1-Day Low 52-Week Low Yield Avg. Volume  
20.840 15.640 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ACAD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 8:40pm ET July 30th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jul 16/14 Jul 15/14 Davis Stephen Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 320,000  
Jul 16/14 Jul 14/14 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Jul 16/14 Jul 14/14 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -20,000 $22.22
Jul 16/14 Jul 14/14 Hacksell Uli Indirect Ownership Common Stock G - Gift 20,000  
Jul 16/14 Jul 14/14 Hacksell Uli Direct Ownership Common Stock G - Gift -20,000  
Jul 16/14 Jul 14/14 Hacksell Uli Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 20,000 $6.86
Jun 18/14 Jun 16/14 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Jun 18/14 Jun 16/14 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -20,000 $23.10
Jun 18/14 Jun 16/14 Hacksell Uli Indirect Ownership Common Stock G - Gift 20,000  
Jun 18/14 Jun 16/14 Hacksell Uli Direct Ownership Common Stock G - Gift -20,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ACAD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 8:40pm ET July 30th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jul 16/14 Jul 15/14 Davis Stephen Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 320,000  
Jul 16/14 Jul 14/14 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Jul 16/14 Jul 14/14 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -20,000 $22.22
Jul 16/14 Jul 14/14 Hacksell Uli Indirect Ownership Common Stock G - Gift 20,000  
Jul 16/14 Jul 14/14 Hacksell Uli Direct Ownership Common Stock G - Gift -20,000  
Jul 16/14 Jul 14/14 Hacksell Uli Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 20,000 $6.86
Jun 18/14 Jun 16/14 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Jun 18/14 Jun 16/14 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -20,000 $23.10
Jun 18/14 Jun 16/14 Hacksell Uli Indirect Ownership Common Stock G - Gift 20,000  
Jun 18/14 Jun 16/14 Hacksell Uli Direct Ownership Common Stock G - Gift -20,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Leslie L. Iversen
Independent Chairman of the Board
Uli Hacksell
President, Chief Executive Officer, Director
Stephen R. Davis
Executive Vice President, Chief Financial Officer and Chief Business Officer
Roger G. Mills
Executive Vice President - Development, Chief Medical Officer
Terrence O. Moore
Executive Vice President, Chief Commercial Officer
Glenn F. Baity
Vice President, General Counsel, Secretary
Company Contact
Address: SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO CA 92121
Tel: N/A
Website: www.acadia-pharm.com
IR: ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Business Overview
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Financial Overview
For the three months ended 31 March 2014, ACADIA Pharmaceuticals Inc. revenues decreased 93% to $30K. Net loss increased from $6.1M to $17.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Research and development increase from $4.2M to $10.7M (expense), Stock-Based Compensation in R&D increase from $254K to $1M (expense).
Employees: 48 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $1,683M as of Mar 31, 2014
Annual revenue (TTM): $0.76M as of Mar 31, 2014
EBITDA (TTM): -$49.97M as of Mar 31, 2014
Net annual income (TTM): -$49.65M as of Mar 31, 2014
Free cash flow (TTM): -$39.93M as of Mar 31, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 98,976,326 as of Apr 30, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
Incyte (OQ:INCY)
Seattle Genetics (OQ:SGEN)